Long-term follow-up of intravesical Epodyl therapy for superficial bladder cancer.

Abstract

The records of 111 patients with multiple superficial grade 1-2 transitional cell tumours of the bladder treated with intravesical Epodyl and followed up for a mean period of 6.4 years were retrospectively analysed. The study showed that 65% of patients responded completely after 12 weekly instillations and 46% of these remained continuously free of disease for 5 years. An initial complete response to therapy and lower pathological grade seemed to indicate a long-term successful response to treatment. In patients who failed to respond by 1 year, further therapy was of no benefit. Clearance of bladder disease by 1 year carried a 14% risk of subsequent tumour invasion by 5 years. This risk increased to 75% in those who failed to respond by 1 year.

• Authors: G R Mufti, J S Virdi, M H Hall
• Journal: British journal of urology (Br J Urol) Vol. 65 Issue 1 Pg. 32-5 (Jan 1990) ISSN: 0007-1331 [Print] England
• PMID: 2310930 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Ethers
• Ethoglucid

Topics

• Administration, Intravesical
• Adult
• Aged
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Carcinoma, Transitional Cell (drug therapy)
• Ethers (therapeutic use)
• Ethoglucid (administration & dosage, therapeutic use)
• Female
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Urinary Bladder Neoplasms (drug therapy)